Rachel Humphrey Sells 13,896 Shares of Pyxis Oncology (NASDAQ:PYXS) Stock

March 26, 2026 by InsiderTrades.com

Key Points

Director Rachel Humphrey sold 13,896 shares of Pyxis Oncology at an average price of $1.03 on April 21, reducing her ownership by 14.6% to 81,309 shares, as disclosed in an SEC Form 4 filing.
Shares were up 5.1%, opening at $1.43 with a market cap of about $89.9 million and a 52‑week range of $0.83–$5.55; the 50‑day and 200‑day moving averages are $1.51 and $2.50, respectively.
Analyst sentiment is mixed but generally favorable: HC Wainwright reiterated a Buy and raised several long‑term EPS estimates, Stifel trimmed its price target to $8.00, and the consensus rating is a Moderate Buy with a $7.00 average price target.

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) Director Rachel Humphrey sold 13,896 shares of the stock in a transaction on Monday, April 21st. The stock was sold at an average price of $1.03, for a total transaction of $14,312.88. Following the sale, the director directly owned 81,309 shares in the company, valued at $83,748.27. This trade represents a 14.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Pyxis Oncology Stock Up 5.1%

Shares of NASDAQ:PYXS opened at $1.43 on Thursday. The company has a market cap of $89.85 million, a PE ratio of -1.11 and a beta of 1.45. Pyxis Oncology, Inc. has a fifty-two week low of $0.83 and a fifty-two week high of $5.55. The firm has a 50-day simple moving average of $1.51 and a 200 day simple moving average of $2.50.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last issued its earnings results on Monday, March 23rd. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.06. The business had revenue of $11.04 million during the quarter. As a group, research analysts forecast that Pyxis Oncology, Inc. will post -1.04 EPS for the current fiscal year.

Trending Headlines about Pyxis Oncology

Here are the key news stories impacting Pyxis Oncology this week:

Positive Sentiment: HC Wainwright reaffirmed its "Buy" rating and $7.00 price target while raising multiple EPS estimates — including FY2026 (from -$1.28 to -$0.95), FY2027 (to -$0.85), FY2028 (to -$0.34), FY2029 (to $0.27) and projecting FY2030 at $0.83 — and also lifted several quarterly forecasts. This analyst backing and upward revisions support a more bullish earnings trajectory for PYXS. HC Wainwright Reaffirms Buy for Pyxis Oncology
Neutral Sentiment: Short‑interest data reported for March appears to show zero shares short (likely a reporting artifact); the published "days to cover" is 0.0 — this item is noisy and provides no clear directional signal.
Negative Sentiment: Stifel Nicolaus lowered its price target from $9.00 to $8.00 (still a Buy) — a downward revision that reduces upside implied by that shop and may temper some investor enthusiasm. Stifel Lowers Expectations for Pyxis Oncology
Negative Sentiment: Insider selling: Director Rachel Humphrey disclosed multiple sales (most recently 13,896 shares at ~$1.03); insider selling can be perceived negatively by investors even if not uncommon for liquidity reasons. SEC filing: Director Form 4 Filing
Negative Sentiment: Within HC Wainwright's note there was a downward revision to Q2 2026 EPS (to -$0.36 from -$0.32), a modest near‑term hit to quarterly guidance amid the broader mixed revisions.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Royal Bank Of Canada lowered their price objective on Pyxis Oncology from $8.00 to $5.00 and set an "outperform" rating for the company in a research note on Thursday, December 18th. Stifel Nicolaus lowered their price target on shares of Pyxis Oncology from $9.00 to $8.00 and set a "buy" rating for the company in a research report on Tuesday. HC Wainwright reiterated a "buy" rating and issued a $7.00 price objective on shares of Pyxis Oncology in a research report on Tuesday. Weiss Ratings reissued a "sell (d-)" rating on shares of Pyxis Oncology in a research note on Thursday, January 22nd. Finally, Wall Street Zen lowered shares of Pyxis Oncology from a "hold" rating to a "sell" rating in a research note on Sunday, March 15th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $7.00.

Check Out Our Latest Report on Pyxis Oncology

Institutional Trading of Pyxis Oncology

Institutional investors have recently made changes to their positions in the stock. Maia Wealth LLC acquired a new stake in Pyxis Oncology in the fourth quarter worth approximately $25,000. Engineers Gate Manager LP bought a new position in shares of Pyxis Oncology during the 4th quarter valued at about $26,000. Fox Run Management L.L.C. acquired a new position in shares of Pyxis Oncology in the 4th quarter worth approximately $26,000. Avanza Fonder AB bought a new stake in Pyxis Oncology during the fourth quarter worth approximately $31,000. Finally, XTX Topco Ltd acquired a new position in Pyxis Oncology in the second quarter worth approximately $40,000. 39.09% of the stock is owned by institutional investors and hedge funds.

About Pyxis Oncology

(Get Free Report)

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company's platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.